HEDS is part of the School of Health and Related Research (ScHARR) at the University of Sheffield. We undertake research, teaching, training and consultancy on all aspects of health related decision science, with a particular emphasis on health economics, HTA and evidence synthesis.

Monday, 25 November 2013

Eculizumab £521,000 per QALY and funded…

…by NHS England.  NHS England are the organisation within the new reoganised NHS that are responsible for developing clinical commissioning polices for specialized services.  Eculizumab for atypical haemolytic uraemic syndrome is one of the most recent set of evaluations that were published in September.  The others were:

  • Stereotactic radiosurgery/radiotherapy for glomus tumours
  • Radiosurgery/radiotherapy for cavernous venous malformations
  • Stereotactic radiosurgery, radiotherapy for ocular melanoma and pituitary adenoma
  • Rituximab for the treatment of systemic lupus erythematosus in adults
  • Plerixafor for stem cell mobilisation
  • Stereotactic radiosurgery/radiotherapy for meningioma
  • Stribild for the treatment of HIV-1 infection in adults

Interestingly, the evaluation of eculizumab is the only one of this set for which a cost-effectiveness analysis was undertaken.  Postive recommendations were made in all the other policies (although not necessarily for the full patient populations).

The first set of policies were published earlier this year.  We haven’t had a look at the methods and recommendations for these.